Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in ALS 

May 20th, 2013

3:00 - 4:00PM EST 

Contact: alstrials@partners.org 

Nazem Atassi, MD, (Massachusetts General Hospital) will present study rationale, results, and next steps for the now completed Phase II Selection Design trial.  After his presentation, Dr. Atassi will be available for questions.    

Interested people can join the webinar on Monday May 20th at 3:00 PM Eastern Standard Time.

Please forward this information to those who may be interested.

Please register to join the meeting by going online to: https://www1.gotomeeting.com/register/897860560 

We recommend that you go online to register for the webinar a day or two before it is scheduled. After registering you will receive a confirmation email containing information about joining the Webinar including dial-in information.

The program will ask that you enter your first and last name upon registration. In the interest of privacy, we ask that you enter your initials only or your first name and last initial.

The Go-To-Webinar software is compatible with the following computer systems:

 - PC Based attendees: Windows® 7, Vista, XP or 2003

 - Server Macintosh Based attendees: Mac OS® X 10.4.11 (Tiger®) or newer

Please register early.  Call-in information will be available for participants from the United States and Canada.